Literature DB >> 7675943

Haloperidol increases smoking in patients with schizophrenia.

J P McEvoy1, O Freudenreich, E D Levin, J E Rose.   

Abstract

Ten patients with schizophrenia participated in 120-min free-smoking sessions when actively psychotic and free of antipsychotic medications, and again after the initiation of haloperidol treatment. During these free-smoking sessions they had access to cigarettes ad libitum. Their expired air carbon monoxide (CO) and plasma nicotine and cotinine levels were measured at the end of the 120-min free-smoking sessions. These patients smoked more after starting haloperidol treatment, relative to their baseline rate of smoking when free of antipsychotic medications, as evidenced by significantly higher expired CO and plasma nicotine levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7675943     DOI: 10.1007/bf02246063

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Prevalence of smoking among psychiatric outpatients.

Authors:  J R Hughes; D K Hatsukami; J E Mitchell; L A Dahlgren
Journal:  Am J Psychiatry       Date:  1986-08       Impact factor: 18.112

2.  Clozapine decreases smoking in patients with chronic schizophrenia.

Authors:  J McEvoy; O Freudenreich; M McGee; C VanderZwaag; E Levin; J Rose
Journal:  Biol Psychiatry       Date:  1995-04-15       Impact factor: 13.382

Review 3.  Effect of nicotine on dynamic function of brain catecholamine neurons.

Authors:  T H Svensson; J Grenhoff; G Engberg
Journal:  Ciba Found Symp       Date:  1990

4.  Normalization of auditory physiology by cigarette smoking in schizophrenic patients.

Authors:  L E Adler; L D Hoffer; A Wiser; R Freedman
Journal:  Am J Psychiatry       Date:  1993-12       Impact factor: 18.112

5.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

Authors:  J P McEvoy; G E Hogarty; S Steingard
Journal:  Arch Gen Psychiatry       Date:  1991-08

6.  Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats.

Authors:  J B Acri; D E Morse; E J Popke; N E Grunberg
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

Review 7.  Basic and clinical psychopharmacology of nicotine.

Authors:  J Le Houezec; N L Benowitz
Journal:  Clin Chest Med       Date:  1991-12       Impact factor: 2.878

  7 in total
  40 in total

1.  Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.

Authors:  Edward D Levin; Joshua E Johnson; Susan Slade; Corinne Wells; Marty Cauley; Ann Petro; Jed E Rose
Journal:  J Pharmacol Exp Ther       Date:  2011-06-02       Impact factor: 4.030

2.  Aripiprazole therapy for nicotine dependence.

Authors:  Sriram Ramaswamy; Subhash C Bhatia
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 3.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 4.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

Review 5.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

6.  Predictors of smoking severity in patients with schizophrenia and alcohol use disorders.

Authors:  Zsuzsa Szombathyne Meszaros; Jacqueline A Dimmock; Robert J Ploutz-Snyder; Ynesse Abdul-Malak; Luba Leontieva; Kelly Canfield; Steven L Batki
Journal:  Am J Addict       Date:  2011-07-18

7.  The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat.

Authors:  David T Chau; Jibran Y Khokhar; Ree Dawson; Jayme Ahmed; Haiyi Xie; Alan I Green
Journal:  Alcohol       Date:  2013-10-17       Impact factor: 2.405

Review 8.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

9.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011

Review 10.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.